BOX WARNING Do not prescribe propoxyphene for patients who are suicidal or addiction-prone.
Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs and patients who use alcohol in excess.
Tell your patients not to exceed the recommended dose and to limit their intake of alcohol.
Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths. Fatalities within the first hour of overdosage are not uncommon. In a survey of deaths due to overdosage conducted in 1975, in approximately 20% of the fatal cases, death occurred within the first hour (5% occurred within 15 minutes). Propoxyphene should not be taken in doses higher than those recommended by the physician. The judicious prescribing of propoxyphene is essential to the safe use of this drug. With patients who are depressed or suicidal, consideration should be given to the use of non-narcotic analgesics. Patients should be cautioned about the concomitant use of propoxyphene products and alcohol because of potentially serious CNS-additive effects of these agents. Because of its added depressant effects, propoxyphene should be prescribed with caution for those patients whose medical condition requires the concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants or other CNS-depressant drugs. Patients should be advised of the additive depressant effects of these combinations.
Many of the propoxyphene-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation or attempts, as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs. Some deaths have occurred as a consequence of the accidental ingestion of excessive quantities of propoxyphene alone or in combination with other drugs. Patients taking propoxyphene should be warned not to exceed the dosage recommended by the physician.
|
NEWS HIGHLIGHTS RELATED TO PROPOXYPHENE AND ACETAMINOPHENMedia Articles Related to Propoxyphene and Acetaminophen (Propoxyphene / Acetaminophen)
New Treatment Eliminates Heel Pain Caused By Plantar Fasciitis Source: Health News from Medical News Today [2008.12.01]
New Pain Management Training Boosts Patient Care, Royal Australian College Of General Practitioners Source: Medical Students / Training News From Medical News Today [2008.12.01]
New Twist on Treatment of Foot Pain (HealthDay) Source: Y! Health News Search RSS Feed [2008.12.01]
Rewiring Of Brain Responsible For Baffling Chronic Pain Source: Neurology / Neuroscience News From Medical News Today [2008.11.30]
Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain Source: Clinical Trials / Drug Trials News From Medical News Today [2008.11.29]
Published Studies Related to Propoxyphene and Acetaminophen (Propoxyphene / Acetaminophen)
Propoxyphene prescribing among populations older and younger than age 65 in a tertiary care hospital. [2007.02]
Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity. [2006.11]
Propoxyphene use and risk for hip fractures in older adults. [2006.09]
Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene. [2006.03]
ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning. [2005]
Clinical Trials Related to Propoxyphene and Acetaminophen (Propoxyphene / Acetaminophen)
Lumbar Stenosis Outcomes Research II [Recruiting]
Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain [Active, not recruiting]
An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee [Completed]
Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression [Terminated]
Neuraxial Pethidine After Lumbar Surgery Trial [Recruiting]
|